How Trial Results Assessing Dara-KRd in Multiple Myeloma May Impact the Treatment Landscape
Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.
Pharmacy Times interviewed Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on his recent presentation at the American Society of Hematology Annual Meeting and Exposition 2021 on the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous transplantation, and minimal residual disease response-adapted consolidation and treatment cessation.
During this video, Costa discusses how the trial results assessing Dara-KRd in patients with newly diagnosed multiple myeloma may impact the treatment landscape.
